Baltimore, MD, United States of America

Sarvajit Chakravarty


Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 1996

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Sarvajit Chakravarty

Introduction

Sarvajit Chakravarty is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of peptide-based therapeutics. His work focuses on creating compounds that can effectively target specific biological pathways.

Latest Patents

Chakravarty holds a patent for "Cyclic bradykinin antagonist peptides." This patent describes cyclic compounds based on a modified bradykinin sequence that serve as potent bradykinin receptor antagonists. The invention involves amino acid substitutions at positions 2 and 5 or 6, which facilitate the cyclization of the peptide through covalent bonding of the amino acid side chains. The analogs produced are useful in treating conditions and diseases in mammals and humans where an excess of bradykinin or related kinins is produced, such as in cases of insect bites. He has 1 patent to his name.

Career Highlights

Chakravarty is currently employed at Scios Nova, Inc., where he continues to innovate and develop new therapeutic solutions. His work has been instrumental in advancing the understanding of bradykinin-related pathways and their implications in various medical conditions.

Collaborations

One of his notable collaborators is Donald J. Kyle, with whom he has worked closely on various projects related to peptide therapeutics.

Conclusion

Sarvajit Chakravarty's contributions to the field of medicinal chemistry highlight the importance of innovative approaches in developing new treatments. His work on cyclic bradykinin antagonist peptides showcases his commitment to addressing significant medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…